Olema Pharmaceuticals (OLMA) News Today $5.15 +0.11 (+2.18%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$5.16 +0.00 (+0.10%) As of 05/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OLMA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period BNP Paribas Financial Markets Makes New $1.13 Million Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)BNP Paribas Financial Markets acquired a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 193,748 shares of the company's stMay 23, 2025 | marketbeat.comOlema Oncology to Participate in Upcoming Investor ConferencesMay 21, 2025 | globenewswire.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Acquired by MPM Bioimpact LLCMPM Bioimpact LLC increased its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 8.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,912,550 shares of the company's stock aftMay 16, 2025 | marketbeat.comParadigm Biocapital Advisors LP Buys 1,801,370 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Paradigm Biocapital Advisors LP increased its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 32.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,3May 16, 2025 | marketbeat.comLightspeed Management Company L.L.C. Makes New Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Lightspeed Management Company L.L.C. bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,930,894 shares ofMay 14, 2025 | marketbeat.comOlema Oncology Reports First Quarter 2025 Financial and Operating ResultsMay 13, 2025 | globenewswire.comDriehaus Capital Management LLC Takes Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Driehaus Capital Management LLC bought a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 220,264 shares oMay 13, 2025 | marketbeat.comBalyasny Asset Management L.P. Buys 418,492 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Balyasny Asset Management L.P. increased its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 59.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,127,589 shares of the company's sMay 12, 2025 | marketbeat.comOlema Oncology to Participate in Upcoming Investor ConferencesMay 9, 2025 | globenewswire.comOlema Pharmaceuticals (OLMA) Projected to Post Earnings on WednesdayOlema Pharmaceuticals (NASDAQ:OLMA) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-olema-pharmaceuticals-inc-stock/)May 9, 2025 | marketbeat.comDeep Track Capital LP Sells 557,167 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Deep Track Capital LP reduced its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 13.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,442,833 shares of the company's stock aftMay 9, 2025 | marketbeat.comBVF Inc. IL Sells 3,420,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)BVF Inc. IL decreased its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 37.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 5,715,893 shares of the company's stock after selling 3,420,000 shares duringMay 6, 2025 | marketbeat.comBoxer Capital Management LLC Invests $3.79 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Boxer Capital Management LLC purchased a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 650,000 shares of the company's stock,May 4, 2025 | marketbeat.comRenaissance Technologies LLC Has $917,000 Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Renaissance Technologies LLC boosted its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 435.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 157,300 shares of the company's stock afterMay 3, 2025 | marketbeat.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comOlema Pharmaceuticals' (OLMA) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a report on Monday.April 30, 2025 | marketbeat.comH.C. Wainwright Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)April 30, 2025 | theglobeandmail.comWalleye Capital LLC Acquires New Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Walleye Capital LLC bought a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 67,007 shares of the company's stock, valued aApril 26, 2025 | marketbeat.comOlema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025April 25, 2025 | globenewswire.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Silverarc Capital Management LLCSilverarc Capital Management LLC reduced its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 48.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 233,281 shares of the company'April 24, 2025 | marketbeat.com1,651,982 Shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Purchased by Avoro Capital Advisors LLCAvoro Capital Advisors LLC purchased a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,651,982 shares of the company's stock, valued atApril 23, 2025 | marketbeat.comBain Capital Life Sciences Investors LLC Invests $43.55 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Bain Capital Life Sciences Investors LLC bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 7,470,214 shares of the company's stock,April 23, 2025 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest UpdateOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) was the target of a large drop in short interest in March. As of March 31st, there was short interest totalling 6,500,000 shares, a drop of 25.2% from the March 15th total of 8,690,000 shares. Based on an average trading volume of 1,090,000 shares, the short-interest ratio is currently 6.0 days. Approximately 14.1% of the company's stock are sold short.April 21, 2025 | marketbeat.comAlliancebernstein L.P. Has $1.83 Million Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Alliancebernstein L.P. increased its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 77.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 313,982 shares of the company's stock after purchasing an additional 137,3April 20, 2025 | marketbeat.comVanguard Group Inc. Grows Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Vanguard Group Inc. grew its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 6.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,685,009 shares of theApril 20, 2025 | marketbeat.comFranklin Resources Inc. Buys 258,625 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Franklin Resources Inc. grew its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 1,714.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 273,706 shares of the company's stock after purchasinApril 16, 2025 | marketbeat.comWellington Management Group LLP Has $8.84 Million Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Wellington Management Group LLP boosted its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 52.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,525,484 shares of the company's stock after buying an additionalApril 12, 2025 | marketbeat.comOlema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable MarketApril 8, 2025 | seekingalpha.comSchroder Investment Management Group Grows Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Schroder Investment Management Group grew its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 548.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 533,111 shares of the company's stockApril 7, 2025 | marketbeat.comPictet Asset Management Holding SA Boosts Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Pictet Asset Management Holding SA raised its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 12.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,883,354 shares of the company's stock after buying an additiApril 4, 2025 | marketbeat.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 | globenewswire.comHighTower Advisors LLC Takes $510,000 Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)HighTower Advisors LLC bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 87,476 shares of the company's stock, valuedMarch 31, 2025 | marketbeat.comJPMorgan Chase & Co. Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $28.00JPMorgan Chase & Co. decreased their price objective on Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating on the stock in a report on Friday.March 29, 2025 | marketbeat.comOlema Oncology price target lowered to $28 from $30 at JPMorganMarch 28, 2025 | markets.businessinsider.comPier Capital LLC Invests $1.59 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Pier Capital LLC purchased a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 272,372 shares of the company's stock, valued at approximately $1,588,000. PiMarch 26, 2025 | marketbeat.comOlema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual MeetingMarch 25, 2025 | globenewswire.comFY2025 Earnings Estimate for OLMA Issued By Lifesci CapitalOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Analysts at Lifesci Capital cut their FY2025 EPS estimates for shares of Olema Pharmaceuticals in a research report issued on Wednesday, March 19th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings per sMarch 22, 2025 | marketbeat.comHC Wainwright Issues Optimistic Estimate for OLMA EarningsOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst E. Bodnar now anticipates that thMarch 22, 2025 | marketbeat.comVictory Capital Management Inc. Sells 758,412 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Victory Capital Management Inc. trimmed its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 89.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 93,100 shares of the company's stock after selling 758,412 shares during the perMarch 22, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for OLMA FY2029 Earnings?Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - HC Wainwright issued their FY2029 EPS estimates for Olema Pharmaceuticals in a report released on Wednesday, March 19th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($2.41) per share for the year. HC WaMarch 21, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Caribou Biosciences (CRBU), Olema Pharmaceuticals (OLMA) and Privia Health Group (PRVA)March 20, 2025 | markets.businessinsider.comOlema Pharmaceuticals (NASDAQ:OLMA) Given "Outperform" Rating at OppenheimerOppenheimer reiterated an "outperform" rating and issued a $25.00 price objective (down previously from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday.March 20, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday.March 20, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Issues Earnings Results, Beats Expectations By $0.12 EPSOlema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.12.March 19, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPSOlema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.12.March 19, 2025 | marketbeat.comOlema Oncology price target lowered to $25 from $30 at OppenheimerMarch 19, 2025 | markets.businessinsider.comOlema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating ResultsMarch 18, 2025 | globenewswire.comOlema Pharmaceuticals (NASDAQ:OLMA) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday.March 6, 2025 | marketbeat.comOlema updated palazestrant combination trial, says OppenheimerMarch 5, 2025 | markets.businessinsider.comOlema Pharmaceuticals (OLMA) Receives a Buy from OppenheimerMarch 5, 2025 | markets.businessinsider.com Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address OLMA Media Mentions By Week OLMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OLMA News Sentiment▼1.141.03▲Average Medical News Sentiment OLMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OLMA Articles This Week▼33▲OLMA Articles Average Week Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADPT News DYN News VERA News ANIP News CALT News OCUL News AMPH News AUPH News MLYS News RCUS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OLMA) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OLMA Stock Free OLMA Stock Alerts